Trial completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • RB1 (RB Transcriptional Corepressor 1) • CCNE1 (Cyclin E1)
|
HER-2 negative • CCNE1 amplification
|
carboplatin • Kisqali (ribociclib) • fulvestrant • BLU-222